Melanoma trials recruiting in Connecticut
All Melanoma trials nationally
23
Recruiting in Connecticut
10
Cities with sites
Cities in Connecticut
New Haven 15Hartford 6Farmington 1Guilford 1Manchester 1New Britain 1North Haven 1Norwalk 1Trumbull 1West Haven 1
Recruiting trials in Connecticut
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
- A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
- A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Integrated Cancer Repository for Cancer Research
- Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
- Project: Every Child for Younger Patients With Cancer
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
- TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
- Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
- The Cancer of the Pancreas Screening-5 CAPS5)Study